The recent arrival of CDK4/6 inhibitor agents. with an approximate doubling of progression-free survival (PFS) associated with their use in hormone receptor-positive. HER2-negative advanced breast cancer (BC). has radically changed the approach to managing this disease. https://www.ivoryjinelle.com/